title: Previstage GCC test for staging patients with colorectal cancer.
abstract: The presence of tumor cells in regional lymph nodes is the most important prognostic and predictive marker in staging patients with colorectal cancer. Cancer cells in lymph nodes are associated with a poorer prognosis and an increased risk of recurrent disease. Additionally, nodal metastases identify patients who derive maximum benefit from adjuvant therapy. However, traditional paradigms for staging patients with colorectal cancer underestimate the extent of metastases and patients whose lymph nodes are ostensibly free of tumor cells by histopathology (pN0) have a 25-30% risk of developing recurrent disease, reflected by the presence of occult nodal metastases. These observations underscore the unmet clinical need for molecular approaches to accurately detect metastatic disease and identify patients at risk for disease relapse that could benefit from adjuvant chemotherapy. Detection of disease-specific mRNA targets as prognostic and predictive markers employing quantitative reverse transcription (qRT)-PCR is an emerging technology that has become a benchmark for individualization of patient management. However, to date, applications of qRT-PCR to detecting occult nodal metastases in colorectal cancer have been equivocal, reflecting markers with suboptimal sensitivity and specificity; limitations of utilizing qualitative, rather than quantitative, RT-PCR; and underpowered study designs based on inadequate patient populations. In that context, guanylyl cyclase C (GCC) is the most sensitive and specific biomarker for metastatic colorectal cancer in extra-intestinal tissues. GCC qRT-PCR detects occult metastases in lymph nodes, providing the most powerful independent prognostic information for predicting disease recurrence in pN0 patients in prospective multicenter clinical trials. This technology forms the basis for the Previstagetrade mark GCC Colorectal Cancer Staging Test encompassing a proprietary multiplex qRT-PCR assay compatible with formalin-fixed, paraffin-embedded lymph nodes for detecting occult metastases. Previstage GCC is a new diagnostic tool that may improve the accuracy of staging, prognosis of clinical outcomes and prediction of therapeutic responses to adjuvant therapy, representing a key advance in the management of patients with colorectal cancer.
authors.affiliation: Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, 132 South 10th Street, 1170 Main, Philadelphia, PA 19107, USA. alex.mejia@jefferson.edu
authors.forename: Alex
authors.initials: A
authors.lastname: Mejia
authors.forename: Scott A
authors.initials: SA
authors.lastname: Waldmana
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology*; D006162:Guanylate Cyclase / Q000032:analysis* / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D025202:Molecular Diagnostic Techniques / Q000379:methods*; D009367:Neoplasm Staging
chemical_list: D014408:Biomarkers, Tumor; D006162:Guanylate Cyclase
references.citation: J Clin Oncol. 2002 Feb 15;20(4):1049-55
references.pmid: 11844829
references.citation: Cancer J. 2003 Jul-Aug;9(4):302-12
references.pmid: 12967141
references.citation: Trends Mol Med. 2003 May;9(5):189-95
references.pmid: 12763523
references.citation: Nat Protoc. 2006;1(3):1559-82
references.pmid: 17406449
references.citation: Int J Colorectal Dis. 2004 Sep;19(5):430-7
references.pmid: 14716495
references.citation: N Engl J Med. 2005 Feb 3;352(5):476-87
references.pmid: 15689586
references.citation: N Engl J Med. 1998 Jul 23;339(4):264-5
references.pmid: 9673307
references.citation: J Clin Oncol. 1998 Aug;16(8):2632-40
references.pmid: 9704713
references.citation: J Clin Oncol. 2002 Oct 15;20(20):4232-41
references.pmid: 12377967
references.citation: Int J Cancer. 2004 Jan 20;108(3):412-7
references.pmid: 14648708
references.citation: Gastroenterology. 2008 May;134(5):1570-95
references.pmid: 18384785
references.citation: Clin Cancer Res. 2006 Aug 1;12(15):4545-52
references.pmid: 16899600
references.citation: Gastroenterol Clin North Am. 2008 Mar;37(1):1-24, v
references.pmid: 18313537
references.citation: Dis Colon Rectum. 1998 Mar;41(3):310-5
references.pmid: 9514425
references.citation: J Clin Oncol. 2005 May 20;23(15):3526-35
references.pmid: 15908663
references.citation: Clin Pharmacol Ther. 2007 Oct;82(4):441-7
references.pmid: 17687268
references.citation: CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308
references.pmid: 15537574
references.citation: J Pathol. 1994 Feb;172(2):183-7
references.pmid: 7513353
references.citation: Hum Pathol. 2005 Feb;36(2):170-9
references.pmid: 15754294
references.citation: J Mol Diagn. 2007 Nov;9(5):563-71
references.pmid: 17916603
references.citation: Pharmacol Rev. 2000 Sep;52(3):375-414
references.pmid: 10977868
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14827-32
references.pmid: 8962140
references.citation: Int J Colorectal Dis. 2004 Mar;19(2):87-94
references.pmid: 13680284
references.citation: Ann Surg. 2007 Oct;246(4):568-75; discussion 575-7
references.pmid: 17893493
references.citation: Eur J Surg. 1996 Aug;162(8):637-42
references.pmid: 8891622
references.citation: Dis Colon Rectum. 1999 Feb;42(2):143-54; discussion 154-8
references.pmid: 10211489
references.citation: Ann Surg. 1993 Sep;218(3):270-5; discussion 275-8
references.pmid: 8373270
references.citation: Ann Surg Oncol. 2001 Mar;8(2):158-62
references.pmid: 11258781
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6871s-6s
references.pmid: 18006792
references.citation: Histopathology. 2007 Mar;50(4):453-64
references.pmid: 17448021
references.citation: Dis Colon Rectum. 1998 Oct;41(10):1244-9
references.pmid: 9788387
references.citation: J Clin Oncol. 1994 Apr;12(4):725-9
references.pmid: 7512130
references.citation: J Clin Oncol. 2001 Oct 1;19(19):3951-9
references.pmid: 11579116
references.citation: Strahlenther Onkol. 2004 Apr;180(4):201-8
references.pmid: 15057430
references.citation: Br J Cancer. 1999 Apr;79(11-12):1813-20
references.pmid: 10206298
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Ann Surg Oncol. 2006 Nov;13(11):1386-92
references.pmid: 17009147
references.citation: Ann Surg Oncol. 2006 Jun;13(6):823-35
references.pmid: 16614884
references.citation: Gastroenterology. 2008 May;134(5):1296-310
references.pmid: 18471507
references.citation: Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6853s-6s
references.pmid: 18006789
references.citation: N Engl J Med. 1998 Jul 23;339(4):223-8
references.pmid: 9673300
references.citation: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8549-56
references.pmid: 16361536
references.citation: Dis Colon Rectum. 1997 Dec;40(12):1465-71
references.pmid: 9407986
references.citation: Expert Rev Mol Diagn. 2005 Sep;5(5):701-13
references.pmid: 16149873
references.citation: Ann Intern Med. 1999 Dec 7;131(11):805-12
references.pmid: 10610624
references.citation: Oncology. 2006;71(5-6):312-9
references.pmid: 17687192
references.citation: Br J Surg. 2001 Oct;88(10):1307-20
references.pmid: 11578283
references.citation: Dis Colon Rectum. 2004 May;47(5):679-86
references.pmid: 15037935
references.citation: Dig Dis Sci. 2003 Dec;48(12):2284-9
references.pmid: 14714614
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: Cancer. 1994 Feb 1;73(3):563-9
references.pmid: 7507795
references.citation: Dis Colon Rectum. 2003 Feb;46(2):221-31
references.pmid: 12576896